Global Transthyretin Amyloidosis Treatment Market Report and Forecast 2023-2031

Global Transthyretin Amyloidosis Treatment Market Report and Forecast 2023-2031

Global Transthyretin Amyloidosis Treatment Market Outlook

The global transthyretin amyloidosis treatment market size was valued at USD 5.07 billion in 2022 and is projected to grow at a CAGR of 7.47% during the forecast period of 2023-2031 to reach a value of USD 9.66 billion by 2031. The market growth can be attributed to the increasing prevalence of transthyretin amyloidosis and the rising awareness about the condition.

Global Transthyretin Amyloidosis Treatment Market: Introduction

Transthyretin amyloidosis treatment involves managing the symptoms and complications associated with the progressive disease caused by the build-up of abnormal transthyretin protein. The condition affects multiple organs and body systems, resulting in a variety of symptoms. Treatment options include medications, lifestyle modifications, and supportive therapies. The increasing prevalence of transthyretin amyloidosis, along with rising awareness and the development of innovative treatment options, is driving the demand for transthyretin amyloidosis treatment.

Advancements in diagnostics and therapeutics have played a significant role in the growth of the transthyretin amyloidosis treatment market. Improved diagnostic techniques have enabled more accurate identification of the condition, leading to better management and treatment outcomes. Moreover, the development of targeted therapies and a better understanding of the underlying mechanisms of the condition contribute to the market's growth. Increased research and investment in transthyretin amyloidosis treatment options have also fostered market expansion.

The transthyretin amyloidosis treatment market is expected to continue to grow in the coming years, as awareness of the condition increases, and new treatment options and technologies are developed to meet the needs of patients with transthyretin amyloidosis. However, there are still significant challenges in diagnosing the condition and providing appropriate treatment, particularly in low- and middle-income countries, where access to healthcare services may be limited.

Transthyretin Amyloidosis Epidemiology

Transthyretin amyloidosis is a rare condition, affecting approximately 1 in 100,000 people worldwide. The disease can affect people of all ages, but it is most diagnosed in middle-aged adults. The increasing prevalence of the condition and the growing demand for effective treatment options are driving the growth of the transthyretin amyloidosis treatment market.

Transthyretin Amyloidosis Treatment Market Segmentations

The market can be segmented based on drug type, diseases type, distribution channel, and region:

Market Breakup by Drug Type

  • Tafamidis
  • Diflunisal
  • Patisiran
  • Inotersen
  • Others
Market Breakup by Diseases Type
  • Hereditary Type Transthyretin Amyloidosis
  • Wild Type Transthyretin Amyloidosis
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Transthyretin Amyloidosis Treatment Market Analysis

The global transthyretin amyloidosis treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of transthyretin amyloidosis, rising awareness about the condition, and the growing demand for innovative treatment options. North America is currently the largest market for transthyretin amyloidosis treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of transthyretin amyloidosis, a well-established healthcare infrastructure, and strong investment in research and development.

Asia Pacific is another region that is experiencing significant growth in the transthyretin amyloidosis treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of transthyretin amyloidosis, and the growing adoption of innovative treatment options. In addition, government initiatives to address the condition are helping to drive the growth of the market in the region.

Key Players in the Global Transthyretin Amyloidosis Treatment Market

The report provides a detailed analysis of the key players involved in the transthyretin amyloidosis treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Sorrento Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Alexion Pharmaceuticals, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Eidos Therapeutics, Inc.
  • Corino Therapeutics, Inc.
  • Prothena Corporation plc

*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Transthyretin Amyloidosis Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Transthyretin Amyloidosis Treatment Market
8.1 Global Transthyretin Amyloidosis Treatment Market Overview
8.2 Global Transthyretin Amyloidosis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Transthyretin Amyloidosis Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Transthyretin Amyloidosis Treatment Market Forecast Value (2023-2031)
8.3 Global Transthyretin Amyloidosis Treatment Market by Drug Type
8.3.1 Market Overview
8.3.1.1 Tafamidis
8.3.1.2 Diflunisal
8.3.1.3 Patisiran
8.3.1.4 Inotersen
8.3.1.5 Others
8.4 Global Transthyretin Amyloidosis Treatment Market by Disease Type
8.4.1 Market Overview
8.4.1.1 Hereditary Type Transthyretin Amyloidosis
8.4.1.1.1 Polyneuropathy
8.4.1.1.2 Cardiomyopathy
8.4.1.1.3 Mixed Type
8.4.1.2 Wild Type Transthyretin Amyloidosis
8.5 Global Transthyretin Amyloidosis Treatment Market by Distribution Channel
8.5.1 Market Overview
8.5.1.1 Hospital Pharmacies
8.5.1.2 Retail Pharmacies
8.5.1.3 Online Pharmacies
8.6 Global Transthyretin Amyloidosis Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 North America Transthyretin Amyloidosis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Transthyretin Amyloidosis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Transthyretin Amyloidosis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Transthyretin Amyloidosis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Transthyretin Amyloidosis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Transthyretin Amyloidosis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sorrento Therapeutics, Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Astellas Pharma Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 AstraZeneca plc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Alexion Pharmaceuticals, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Spectrum Pharmaceuticals, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Pfizer Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Alnylam Pharmaceuticals, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Ionis Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Eidos Therapeutics, Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Corino Therapeutics, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Prothena Corporation plc
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Transthyretin Amyloidosis Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings